ResMed RMD Cash Flow Statement
| TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|---|---|
| $1.52B+15.7% | $1.49B+19.0% | $1.44B+29.2% | $1.4B+37.2% | $1.31B+37.0% | ||
| $220.19M+23.3% | $204.89M+14.9% | $201.44M+14.0% | $198.47M+12.2% | $178.52M-0.8% | ||
| $101.64M+15.1% | $98.97M+17.0% | $92.67M+13.2% | $91.66M+14.3% | $88.3M+12.2% | ||
| $64.78M-49.8% | $87.96M-39.5% | $83.13M-20.4% | $76.68M-42.9% | $128.99M+36.0% | ||
| $8.19M— | —— | —— | —— | —— | ||
| $171.25M+4.5% | $130.46M-4.2% | $124.03M+27.0% | $90.96M-25.5% | $163.85M+38,362% | ||
| $105.39M+644% | -$22.3M-126% | -$85.06M-216% | -$82.63M-172% | -$19.38M-113% | ||
| —— | —— | -$15.81M-283% | -$10.3M-155% | -$23.24M— | ||
| $43.13M+14.2% | $41.31M+1.5% | $38.33M-3.7% | $37.34M-5.1% | $37.76M+2.9% | ||
| —— | —— | —— | $3.64M+297% | $2.27M+158% | ||
| $1.89B+14.3% | $1.91B+29.7% | $1.88B+30.7% | $1.75B+25.0% | $1.65B+37.9% | ||
| $135.74M+61.3% | $122.89M+45.3% | $114.99M+31.8% | $89.87M-9.6% | $84.16M-22.8% | ||
| —— | —— | $139.77M+362% | $139.25M+4.3% | $20.37M-82.3% | ||
| $28.55M+282% | $10.47M+34.1% | $7.24M-30.6% | $6.42M-49.7% | $7.48M-38.7% | ||
| $3M-41.5% | $500K— | $500K— | $4.63M— | $5.13M— | ||
| —— | —— | $11.82M+86.7% | $10.78M-30.0% | $1.44M-92.1% | ||
| -$295.26M-162% | -$269.02M-136% | -$254.77M-115% | -$200.05M+25.8% | -$112.84M+58.2% | ||
| $340.16M+12.0% | $330.63M+11.5% | $320.74M+10.7% | $310.88M+10.1% | $303.84M+9.9% | ||
| $600.05M+140% | $500.06M+122% | $400.03M+100.0% | $300.03M+100% | $250.02M+150% | ||
| —— | $10M-98.2% | $10M-98.5% | $40M-95.2% | $335M-50.7% | ||
| $75.35M+4.7% | $76.94M+13.4% | $74.26M+22.8% | $74.44M+40.2% | $71.98M+47.2% | ||
| $22.04M+23.0% | $21.98M+23.1% | $18.41M+106% | $18.08M+106% | $17.91M+107% | ||
| -$907.75M-8.6% | -$796.58M+22.5% | -$685.77M+38.7% | -$606.25M+45.8% | -$835.65M— | ||
| $40.85M+518% | $46.23M+301% | $14.66M+3.3% | $25.8M+1,496% | -$9.77M-134% | ||
| $727.8M+4.7% | $895.13M+187% | $957.49M+341% | $971.09M+9,175% | $694.8M+6,837% | ||
| $26.91M-2.1% | $34.6M+42.4% | $27.98M-26.6% | $28.48M-37.7% | $27.49M-49.8% | ||
| $297.27M— | —— | —— | —— | —— | ||
| —— | —— | -$15.81M-283% | -$10.3M-155% | -$23.24M— | ||
| $5.99M— | $4.61M— | $4.17M— | $3.64M— | —— | ||
| —— | —— | —— | $3.64M+297% | $2.27M+158% | ||
| $105.39M+644% | -$22.3M-126% | -$85.06M-216% | -$82.63M-172% | -$19.38M-113% | ||
| —— | —— | —— | $0— | $0-100% | ||
| $43.13M+14.2% | $41.31M+1.5% | $38.33M-3.7% | $37.34M-5.1% | $37.76M+2.9% | ||
| —— | —— | —— | —— | —— | ||
| -$47.97M— | —— | —— | —— | —— | ||
| —— | —— | $139.77M+349% | $140.1M+4.0% | $21.22M-82.2% | ||
| —— | —— | $11.82M+86.7% | $10.78M-30.0% | $1.44M-92.1% | ||
| $3M-41.5% | $500K— | $500K— | $4.63M— | $5.13M— | ||
| —— | —— | —— | $10.86M— | $8.14M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $0-100% | $8.31M-69.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $670K+217% | -$286K-121% | ||
| —— | —— | $102.64M+477% | $101.32M+9.9% | $14.48M-81.4% | ||
| $297.27M— | —— | —— | —— | —— | ||
| —— | —— | $42.74M+258% | $43.53M-5.4% | $7.51M— | ||
| $1.75B+11.8% | $1.79B+28.7% | $1.77B+30.7% | $1.66B+27.6% | $1.57B+44.0% | ||
| $1.75B+11.8% | $1.79B+28.7% | $1.77B+30.7% | $1.66B+27.6% | $1.57B+44.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does ResMed generate?
- ResMed (RMD) generated $1.9B in operating cash flow over the trailing twelve months.
- What is ResMed's free cash flow?
- After $135.7M of capital expenditures, ResMed's free cash flow was $1.8B over the trailing twelve months, up 11.8% year over year.
- Where does ResMed's cash flow data come from?
- Every line is extracted from ResMed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
